You have successfully emailed the post. From advances in cancer drugs to using genomics to better understand diseases, here are the ways leaders diagnostics of cognitive development in young children 40 in biotech and pharma are changing medicine.
It’s an exciting time to be in the biotech and pharmaceutical industries. From advances in cancer treatments to using genomics to better understand diseases, to technologies that let you edit, silence, or otherwise manipulate genes, the young leaders in the industry are paving their way through their businesses with biomedical research that sounds closer to science fiction than actual medicine. Because many of those in the biotechnology and pharmaceutical industries attend graduate school for years before joining a company, leaders under the age of 40 and especially 30 tend to be less common than in other industries. Business Insider came up with a list of 30 leaders, through nominations and past coverage, who are shaping the future of medicine. We asked them what the contribution the under-40 generation would have on medicine.
Here’s who’s doing groundbreaking work as young leaders under 40 in biopharma, listed alphabetically. Narges Bani Asadi, 36, wants to make human-genome analysis more useful to people. Narges Bani Asadi, the vice president and Life Cycle Leader of sequencing genomics at Roche Sequencing Informatics, grew up in Iran before moving to Stanford University for graduate school. While pursuing a master’s and later a Ph. It blew my mind,” she said. From there, she started working at that intersection between computer science and medicine, launching a startup called Bina that was later acquired by Roche. The company worked to find clinical applications for genomic data, so that the findings that come out of academic researchers make it to patients.